KDM1A and essential thrombocythemia: LSD1 inhibitors, particularly bomedemstat (IMG-7289) (Table 1), represent a novel therapeutic approach for MPNs, with significant progress made in their clinical development for essential thrombocythemia (ET) and (pre-fibrotic) myelofibrosis (MF) [140].